Cyclerion Therapeutics, Inc. (CYCN)
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.1M
- Net income
- -$3.5M
- Total assets
- $10.0M
- Market cap
- $12.9M
- Operating margin
- -239.8%
- Net margin
- -170.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.1M
- Operating expenses
- $7.0M
- Operating income
- -$5.0M
- Income tax
- $0
- Net income
- -$3.5M
- EPS (basic)
- $-1.11
- EPS (diluted)
- $-1.11
Balance sheet
- Total assets
- $10.0M
- Current assets
- $4.6M
- Total liabilities
- $900.0K
- Current liabilities
- $900.0K
- Shareholders’ equity
- $9.1M
Cash flow
- Operating cash flow
- -$3.3M
- Investing cash flow
- -$8.0K
- Financing cash flow
- $3.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $12.9M
- EPS (diluted)
- $-1.11
- Shares outstanding
- 3.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 18, 2019
Cyclerion Therapeutics, Inc. (CYCN) Stock Price
- Reported a net loss of $3.5M in FY2025.
- Revenue declined 47% from FY2021 to FY2025.
- Trading 45% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cyclerion Therapeutics, Inc..
Write a review
News about Cyclerion Therapeutics, Inc.
News & sentiment via Polygon.io
Cyclerion Therapeutics, Inc.: frequently asked questions
Is Cyclerion Therapeutics, Inc. an American company?
Cyclerion Therapeutics, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Cyclerion Therapeutics, Inc. headquartered?
Cyclerion Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Cyclerion Therapeutics, Inc. publicly traded?
Yes — Cyclerion Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol CYCN on the NASDAQ.
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
